Skip to main content
. 2015 Jan 1;5(1):86–96. doi: 10.7150/thno.10062

Figure 3.

Figure 3

Monitoring the sensitivity of hNIS- or opt-hNIS gene-expressing tumor cells in vitro and in vivo. (A) γ-camera images of cell culture plates. 99mTc-pertechnetate uptake increased in a dose-dependent manner in both hNIS- and opt-hNIS-expressing cells, but signals from opt-NIS-expressing cells were stronger than those from hNIS-expressing cells under the same dose of radiation. (B) The amount of 99mTc-pertechnetate uptake by opt-hNIS-expressing cells was significantly higher than uptake by hNIS-expressing cells. All experiments were performed in triplicate, and bars represent means ±SD (*, P<0.001). (C) In vivo tumor xenograft models were established using MDA-MB-231/luc cells expressing hNIS or opt-hNIS. Increased uptake of 99mTc-pertechnetate was observed in opt-hNIS xenografts, compared to hNIS xenografts (n=5; *, P<0.001). Regions of interest (ROIs) were drawn over tumor regions to quantify emitted luminescence. (D) SPECT/CT imaging of hNIS- or opt-hNIS-expressing tumors exposed to different doses of 99mTc-pertechnetate for one hour and subcutaneously implanted in a nude mouse. Only 3.12 μCi of 99mTc-pertechnetate was necessary to visualize cells expressing opt-hNIS in subcutaneous grafts.